LCA10/CEP290 gene therapy(Saliogen Therapeutics)

N/A

Report date: 2024/05/13 16:58:22

Base Information

Drug NameLCA10/CEP290 gene therapy(Saliogen Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionCentrosomal protein of 290 kDa modulators
TargetsCentrosomal protein of 290 kDa
Therapy Area/IndicationsRetinal Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSaliogen Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSaliogen Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsRetinal Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A